Sinsin Pharmaceutical신신제약
002800 · KOSDAQ · ₩002800 · 신신제약
₩4,060▲ ₩25 (0.62%)End-of-day · Oct 28, 2026 · End-of-day prices.
Filings
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 1, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획자진취하등) (과민성 방광 치료제 UIP620의 제3상 임상시험 조기종료)May 22, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획자진취하등) (불면증 환자의 단기치료제 SS262의 제1상 임상시험 조기종료)May 22, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Change of Department Affiliation소속부변경Apr 30, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 26, 2026Open on DART
- Audit report submitted감사보고서제출Mar 18, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 18, 2026Open on DART
- Amended: Notice of shareholders' meeting[기재정정]주주총회소집공고Mar 12, 2026Open on DART
- Amended: Shareholders' meeting called[기재정정]주주총회소집결의Mar 11, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 11, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 11, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Feb 10, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Feb 9, 2026Open on DART
- Cash dividend decision현금ㆍ현물배당결정Feb 9, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 2, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 12, 2025Open on DART
- Major Matters Report (Business Suspension)주요사항보고서(영업정지)Nov 19, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 29, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 2, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
- Quarterly report (Mar 2025)분기보고서 (2025.03)May 14, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 26, 2025Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 26, 2025Open on DART
- Audit report submitted감사보고서제출Mar 18, 2025Open on DART
- Annual report (Dec 2024)사업보고서 (2024.12)Mar 18, 2025Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 11, 2025Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 11, 2025Open on DART
- Shareholders' meeting called주주총회소집결의Feb 5, 2025Open on DART
- Cash dividend decision현금ㆍ현물배당결정Feb 5, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 22, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 14, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 14, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 12, 2024Open on DART
- Quarterly report (Sep 2024)분기보고서 (2024.09)Nov 14, 2024Open on DART
- Half-year report (Jun 2024)반기보고서 (2024.06)Aug 14, 2024Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (과민성 방광 환자를 대상으로 UIP620의 유효성 및 안전성을 평가하기 위한 무작위배정, 이중눈가림, 다기관, 제3상 임상시험계획IND 승인)Jul 15, 2024Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (불면증 환자의 단기치료제 SS262의 임상 1상 임상시험계획IND 승인)May 28, 2024Open on DART
- Quarterly report (Mar 2024)분기보고서 (2024.03)May 14, 2024Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (과민성 방광 환자를 대상으로 UIP620의 유효성 및 안전성을 평가하기 위한 무작위배정, 이중눈가림, 다기관, 제3상 임상시험)Apr 17, 2024Open on DART
- Trading halt주권매매거래정지 (중요한 영업정지)Apr 15, 2024Open on DART
- Major Matters Report (Business Suspension)주요사항보고서(영업정지)Apr 15, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 28, 2024Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Mar 28, 2024Open on DART
- Annual general meeting results정기주주총회결과Mar 21, 2024Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 21, 2024Open on DART
- Audit report submitted감사보고서제출Mar 13, 2024Open on DART
- Annual report (Dec 2023)사업보고서 (2023.12)Mar 13, 2024Open on DART
Titles in Korean until English translations are added.
Also known as: Sinsin Pharmaceutical / 신신제약 / 002800 / KRX:002800
Source: KRX statistical information